178 related articles for article (PubMed ID: 11295597)
1. Androgen antagonists: Potential role in prostate cancer prevention.
Trump DL; Waldstreicher JA; Kolvenbag G; Wissel PS; Neubauer BL
Urology; 2001 Apr; 57(4 Suppl 1):64-7. PubMed ID: 11295597
[TBL] [Abstract][Full Text] [Related]
2. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.
Azzouni F; Mohler J
Urology; 2012 Jun; 79(6):1197-205. PubMed ID: 22446342
[TBL] [Abstract][Full Text] [Related]
3. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
[TBL] [Abstract][Full Text] [Related]
4. Hormonal prevention of prostate cancer.
Brawley OW
Urol Oncol; 2003; 21(1):67-72. PubMed ID: 12684130
[TBL] [Abstract][Full Text] [Related]
5. [Chemoprevention of prostate cancer. Current status].
Schmitz-Dräger BJ; Lümmen G; Schäfer RM
Urologe A; 2007 Jun; 46(6):611-5. PubMed ID: 17483928
[TBL] [Abstract][Full Text] [Related]
6. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
Helfand BT; Blackwell RH; McVary KT
J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154
[TBL] [Abstract][Full Text] [Related]
7. Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA; Laufer M; Vogelzang NJ; Sartor O; Thornton D; Neubauer BL; Sinibaldi V; Lieskovsky G; Carducci MA; Zahurak M; Raghavan D
Urology; 2004 Jan; 63(1):114-9. PubMed ID: 14751361
[TBL] [Abstract][Full Text] [Related]
8. The future of prostate cancer prevention.
Brawley OW; Barnes S; Parnes H
Ann N Y Acad Sci; 2001 Dec; 952():145-52. PubMed ID: 11795434
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
10. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
11. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
12. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer prevention trial yields positive results, but with a few cautions.
Reynolds T
J Natl Cancer Inst; 2003 Jul; 95(14):1030-1. PubMed ID: 12865442
[No Abstract] [Full Text] [Related]
14. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
15. 5alpha-reductase inhibitors: what role should they play?
Kaplan SA
Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
[TBL] [Abstract][Full Text] [Related]
16. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
17. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy.
Pascal LE; Masoodi KZ; O'Malley KJ; Shevrin D; Gingrich JR; Parikh RA; Wang Z
J Urol; 2015 Apr; 193(4):1388-93. PubMed ID: 25444984
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
19. Finasteride.
Chaudhary UB; Turner JS
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):873-81. PubMed ID: 20536414
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143.
Homma Y; Kaneko M; Kondo Y; Kawabe K; Kakizoe T
J Natl Cancer Inst; 1997 Jun; 89(11):803-7. PubMed ID: 9182979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
